Seller record · Telehealth service

Kin Meds

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S5, analytical documentation: No certificate of analysis or lot document is published on the product pages, in the answers or in the terms, privacy and returns policies. 1 more criterion also fails; see the table below.

At a glance

Kin MedsTelehealth service

6/8criteria passed
Price
Semaglutide $199, tirzepatide from $249 a month
Sells
compounded semaglutide, compounded tirzepatide with B12, microdose GLP-1, and 10 more
FDA letters
1 on file
Visit Kin MedsSee all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded semaglutide and tirzepatide plans at flat monthly prices, with sermorelin, NAD+, glutathione, GHK-Cu cream and PT-141, and consultation plans for Wegovy, Zepbound and Foundayo. It names Rush Pharmacy as its pharmacy, prints two different addresses for itself, and was named in an FDA warning letter in February 2026.

Operating entity No legal entity name appears in the footer, on the contact page, in the terms or in the privacy policy.

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSKin Meds' FAQ
S2Prescription gatingPASSKin Meds' weightloss page on its intake site; Kin Meds' FAQ
S3Pharmacy identificationPASSKin Meds' FAQ; Kin Meds' returns and refund policy
S4Compounding disclosurePASSKin Meds' GLP-1 page; Kin Meds' sermorelin page
S5Analytical documentationFAILKin Meds' all treatments page; Kin Meds' FAQ
S6Business addressFAILKin Meds' privacy policy; Kin Meds' hipaa notice; Kin Meds' returns and refund policy
S7Price disclosurePASSKin Meds' website; Kin Meds' GLP-1 page; Kin Meds' all treatments page; Kin Meds' wegovy page
S8Enforcement statusPASSfda.gov; letter 721450

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSUS-based doctors review each patient's answers and prescribe only as necessary, and some states require a video or live chat consultation first.Source: Kin Meds' FAQ.
S2PASSEvery Start My Free Visit button opens a health assessment that begins with an account screen and telehealth consent, and the site has no cart. The answers state that the card is billed when the medication ships.Source: Kin Meds' weightloss page on its intake site; Kin Meds' FAQ.
S3PASSRush Pharmacy is named as the pharmacy in the answers, and the privacy and returns policies print it at 1977 Alafaya Trail #1121, Oviedo, FL 32765. The returns policy also gives a return address at Strive Pharmacy, 1275 E Baseline Rd #104, Gilbert, AZ 85233.Source: Kin Meds' FAQ; Kin Meds' returns and refund policy.
S4PASSEach compounded product page states that the medication is compounded and dispensed by a licensed third-party pharmacy and that compounded medications are not FDA-approved, and every footer repeats that they have not been reviewed by the FDA for safety, efficacy, or quality.Source: Kin Meds' GLP-1 page; Kin Meds' sermorelin page.
S5FAILNo certificate of analysis or lot document is published on the product pages, in the answers or in the terms, privacy and returns policies.Source: Kin Meds' all treatments page; Kin Meds' FAQ.
S6FAILKin Meds prints two different addresses for itself. The privacy contact section and the HIPAA notice give 2006 N Sepulveda Blvd #1102, Manhattan Beach, CA 90266, while the privacy retention section and the returns policy give Kin Meds and Rush Pharmacy at 1977 Alafaya Trail #1121, Oviedo, FL 32765.Source: Kin Meds' privacy policy; Kin Meds' hipaa notice; Kin Meds' returns and refund policy.
S7PASSSemaglutide is printed at $199 a month at every dose and the tirzepatide plan from $249 a month, with sermorelin injection from $349, NAD+ injection and glutathione from $249, NAD+ nasal spray from $349 and GHK-Cu face cream from $199. The Wegovy, Zepbound and Foundayo plans start at $149 a month for the consultation.Source: Kin Meds' website; Kin Meds' GLP-1 page; Kin Meds' all treatments page; Kin Meds' wegovy page.
S8PASSFDA warning letter 721450, February 2026, names Kin Meds after reviewing Kin Meds' website, alleging that its compounded semaglutide and tirzepatide are misbranded because the pictured labels suggest Kin Meds is the compounder and because its same active ingredient claims imply FDA approval. No close-out letter appears in the index. No FDA action has halted the business, and the seller continues to operate.Source: fda.gov; letter 721450.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide with B12, microdose GLP-1, sermorelin injection, NAD+ injection and nasal spray, glutathione, GHK-Cu face cream, PT-141 injection, PT-141 with tadalafil and oxytocin, Wegovy, Zepbound, Foundayo, estradiol cream.

Other sellers of the same products

Who sells semaglutideWho sells tirzepatideWho sells sermorelinWho sells NAD+Who sells glutathioneWho sells PT-141Who sells GHK-Cu

Enforcement documents on file: 1 warning letter

FDA warning letter 721450, issued February 2026, to Kin MedsThe pictured labels on Kin Meds' website suggest Kin Meds is the compounder of its compounded semaglutide and tirzepatide, and its claims of the same active ingredient as brand-name drugs imply FDA approval; both are false or misleading.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Unpaid link. Kin Meds does not pay the site, and nothing is earned when it is used. Funding.

Visit Kin Meds

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.